Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Real-time symptom monitoring using a mobile phone is potentially advantageous for patients receiving oral chemotherapy. We therefore conducted a pilot study of patient dose adaptation using mobile phone monitoring of specific symptoms to investigate relative dose intensity of capecitabine, level of toxicity and perceived supportive care.Patients with breast or colorectal cancer receiving capecitabine completed a symptom, temperature and dose diary twice a day using a mobile phone application. This information was encrypted and automatically transmitted in real time to a secure server, with moderate levels of toxicity automatically prompting self-care symptom management messages on the screen of the patient's mobile phone or in severe cases, a call from a specialist nurse to advise on care according to an agreed protocol.Patients (n = 26) completed the mobile phone diary on 92.6 % of occasions. Twelve patients had a maximum toxicity grade of 3 (46.2 %). The average dose intensity for all patients as a percentage of standard dose was 90 %. In eight patients, the dose of capecitabine was reduced, and in eight patients, the dose of capecitabine was increased. Patients and healthcare professionals involved felt reassured by the novel monitoring system, in particular, during out of hours.It is possible to optimise the individual dose of oral chemotherapy safely including dose increase and to manage chemotherapy side effects effectively using real-time mobile phone monitoring of toxicity parameters entered by the patient.

Original publication

DOI

10.1007/s00520-014-2224-1

Type

Journal article

Journal

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Publication Date

10/2014

Volume

22

Pages

2677 - 2685

Addresses

Oxford University Hospitals NHS Trust, Oxford, OX3 7LE, UK.

Keywords

Humans, Breast Neoplasms, Colorectal Neoplasms, Fluorouracil, Deoxycytidine, Antimetabolites, Antineoplastic, Monitoring, Physiologic, Pilot Projects, Adult, Aged, Middle Aged, Female, Male, Cell Phones, Capecitabine